Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CFSAN 2005 Priorities: “Per Day” Labeling, NDI Revised Definitions

This article was originally published in The Tan Sheet

Executive Summary

Publishing a final rule on "per day" labeling for dietary supplements is an "A" level priority for the Center for Food Safety & Applied Nutrition in the upcoming year
Advertisement

Related Content

Qualified Health Claim Draft Guidance Should Top CFSAN ‘06 Priorities – CHPA
Qualified Health Claim Draft Guidance Should Top CFSAN ‘06 Priorities – CHPA
Qualified Health Claim Draft Guidance Should Top CFSAN ‘06 Priorities – CHPA
CFSAN programming
CFSAN programming
Dietary Supplement Reps Ask FDA For Clarity Across The Board On NDIs
FDA’s Crawford Outlines DSHEA “Umbrella Strategy” For Supplements
Qualified Health Claims Scientific Evidence To Be Assessed, Ranked By FDA
Supplement Labeling of "Per Day" Ingredient Amount Proposed by FDA
Supplement Labeling of "Per Day" Ingredient Amount Proposed by FDA

Topics

Advertisement
UsernamePublicRestriction

Register

PS097585

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel